{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:36:15Z","timestamp":1766064975097,"version":"build-2065373602"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2002,5,28]],"date-time":"2002-05-28T00:00:00Z","timestamp":1022544000000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2002,5]]},"abstract":"<jats:p>\n                    <jats:bold>OBJECTIVES:<\/jats:bold>\n                    To evaluate the efficacy, safety, and tolerability of a new, once\u2010daily extended\u2010release (ER) formulation of tolterodine in treating overactive bladder in older (\u226565) and younger (&lt;65) patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>DESIGN:<\/jats:bold>\n                    A 12\u2010week double\u2010blind, placebo\u2010controlled clinical trial.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>SETTING:<\/jats:bold>\n                    An international study conducted at 167 medical centers.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>PARTICIPANTS:<\/jats:bold>\n                    One thousand fifteen patients (43.1% aged \u226565) with urge incontinence and urinary frequency.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>INTERVENTION:<\/jats:bold>\n                    Patients were randomized to treatment with tolterodine ER 4 mg once daily (qd) (n = 507) or placebo (n = 508) for 12 weeks.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>MEASUREMENTS:<\/jats:bold>\n                    Efficacy, measured with micturition charts (incontinence episodes, micturitions, volume voided per micturition) and subjective patient assessments, safety, and tolerability endpoints were evaluated, relative to placebo, according to two age cohorts: younger than 65 and 65 and older.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    Mean age in the older and younger patient cohorts was 74 (range 65\u201393) and 51 (range 20\u201364), respectively. Compared with placebo, significant improvements in micturition chart variables with tolterodine ER showed no age\u2010related differences. Irrespective of age, significantly more tolterodine ER recipients than placebo recipients reported an improvement in urgency symptoms. After 12 weeks of treatment with tolterodine ER, a fivefold increase in the percentage of patients able to finish tasks before voiding in response to urgency was noted in both age groups (&lt;65: from 6.5\u201332.8%, \u226565: from 5.1\u201326.2%). Tolterodine ER recipients, irrespective of age, also had significant improvements in their bladder condition than did placebo recipients. Overall, a greater percentage of patients, irrespective of age, perceived any benefit with tolterodine ER than with placebo (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .001). Dry mouth (of any severity) was the most common adverse event in both the tolterodine ER and placebo treatment arms, irrespective of age (&lt;65: ER 22.7%, placebo 8.1%; \u226565: ER 24.3%, placebo 7.2%). Few patients (&lt;2%) experienced severe dry mouth. No central nervous system, visual, cardiac (per electrocardiogram), or laboratory safety concerns were noted. Withdrawal rates due to adverse events on tolterodine ER 4 mg qd were comparable in the two age cohorts (&lt;65: 5.5%; \u226565: 5.1%;\n                    <jats:italic>P<\/jats:italic>\n                    = .87).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSIONS:<\/jats:bold>\n                    The new, once\u2010daily ER formulation of tolterodine is efficacious, safe, and well tolerated in the treatment of patients with symptoms of overactive bladder, irrespective of age.\n                  <\/jats:p>","DOI":"10.1046\/j.1532-5415.2002.50203.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T00:37:24Z","timestamp":1047429444000},"page":"799-807","source":"Crossref","is-referenced-by-count":140,"title":["Efficacy, Safety, and Tolerability of Extended\u2010Release Once\u2010Daily Tolterodine Treatment for Overactive Bladder in Older versus Younger Patients"],"prefix":"10.1111","volume":"50","author":[{"given":"Norman R.","family":"Zinner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Mattiasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart L.","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,5,28]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study.","volume":"87","author":"Milsom I","year":"2001","journal-title":"BJU Int"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00580-3"},{"key":"e_1_2_7_4_2","first-page":"56","article-title":"The overactive bladder: An overview for primary care health providers.","volume":"44","author":"Wein AJ","year":"1999","journal-title":"Int J Fertil Womens Med"},{"volume-title":"The Overactive Bladder. A Widespread and Treatable Condition","year":"1998","author":"Abrams P","key":"e_1_2_7_5_2"},{"key":"e_1_2_7_6_2","first-page":"731","volume-title":"Incontinence. Proceedings of the 1st International Consultation on Incontinence. Monaco, June 28\u2013July 1 1998","author":"Fonda D","year":"1999"},{"key":"e_1_2_7_7_2","first-page":"60","article-title":"Oxybutynin. The clinical experience.","volume":"3","author":"Appell RA","year":"1991","journal-title":"Contemp Urol"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1998.tb01006.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365599509180578"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2000.00623.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440350031003"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66326-4"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2001.49144.x"},{"key":"e_1_2_7_14_2","first-page":"229","article-title":"Tolterodine: Selectivity for the bladder over effects on visual accommodation.","volume":"163","author":"Chancellor MB","year":"2000","journal-title":"J Urol"},{"key":"e_1_2_7_15_2","first-page":"13","article-title":"The mechanism of action of tolterodine.","volume":"11","author":"Nilvebrant L","year":"2000","journal-title":"Rev Contemp Pharmacother"},{"key":"e_1_2_7_16_2","first-page":"253","article-title":"Tolterodine once daily: Selectivity for the bladder over effects on salivation compared to Ditropan\u00ae XL.","volume":"165","author":"Chapple CR","year":"2001","journal-title":"J Urol"},{"key":"e_1_2_7_17_2","first-page":"125","article-title":"Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice.","volume":"51","author":"Pahlman I","year":"2001","journal-title":"Arzneim Forsch Drug Res"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010528"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00717.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00599-2"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001920050014"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007094"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(00)01113-4"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17424"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00597-9"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200019020-00001"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200118070-00007"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68810-6"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199915020-00004"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/08959374960100011301"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/014556139907800707"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1995.tb05815.x"},{"key":"e_1_2_7_33_2","first-page":"69","article-title":"Drugs and the aging brain.","volume":"43","author":"Gordon M","year":"1988","journal-title":"Geriatrics"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002400050169"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7119.1363"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1988.tb04356.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199506030-00007"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1532-5415.2002.50203.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1532-5415.2002.50203.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:56:32Z","timestamp":1762188992000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1046\/j.1532-5415.2002.50203.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["10.1046\/j.1532-5415.2002.50203.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1532-5415.2002.50203.x","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"type":"print","value":"0002-8614"},{"type":"electronic","value":"1532-5415"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}